Financial Performance - The company reported a revenue of CNY 277.09 million in 2024, a decrease of 5.05% compared to 2023[24]. - Net profit attributable to shareholders was CNY 39.28 million, down 27.99% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 24.53 million, a decline of 40.12%[25]. - Basic and diluted earnings per share decreased by 41.82% to CNY 0.32 in 2024[23]. - The weighted average return on equity fell to 3.34%, a decrease of 6.5 percentage points from the previous year[23]. - The company's comprehensive gross margin for the reporting period was 40.08%, an increase from 39.48% in the previous period, indicating strong market position and competitive strength[86]. - The company's inventory value at the end of the reporting period was 145.91 million yuan, accounting for 14.75% of current assets, highlighting the significant inventory levels related to the PEEK industry[86]. - Accounts receivable at the end of the reporting period amounted to 46.52 million yuan, with 93.86% of it due within one year, reflecting a healthy aging structure[87]. - The company's operating revenue for 2024 was CNY 277.09 million, a decrease of 5.05% year-on-year, primarily due to a voluntary price reduction on certain products[94]. - The operating cost decreased by 6.00% year-on-year to CNY 166.03 million, attributed to effective procurement strategies and production process improvements[95]. Dividend Policy - The company plans to distribute a cash dividend of 2.00 RMB per 10 shares, totaling 24,336,000.00 RMB, which represents 61.95% of the net profit attributable to shareholders for the year[6]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2024 fiscal year[6]. - The company has a cash dividend policy that mandates a minimum of 10% of the distributable profits to be allocated as cash dividends each year[198]. - The company has a policy to prioritize cash dividends unless significant investment plans arise, in which case the dividend ratio may be adjusted[198]. - The company mandates a minimum cash dividend ratio of 40% for mature-stage companies with significant capital expenditure plans[199]. - For growth-stage companies with significant capital expenditure plans, the minimum cash dividend ratio is set at 20%[199]. - The board must ensure that stock dividends align with the company's operational scale and profit growth rate[199]. Research and Development - The company achieved a total R&D investment of CNY 31,924,137.16, representing a 38.36% increase compared to the previous year[67]. - R&D expenses accounted for 11.52% of total revenue, an increase of 3.61 percentage points from the previous year[67]. - The company obtained 5 new patents during the reporting period, bringing the total number of patents to 34, including 25 invention patents[65]. - The company has developed two new grades of medical-grade PEEK resin products, ZR3G and ZR7G, to meet the growing demand in the medical sector[69]. - The company is actively pursuing technology upgrades and product innovation to maintain its competitive edge, leading to increased R&D investment[25]. - The company has been recognized as a national-level "Little Giant" enterprise for specialized and innovative manufacturing in 2024[64]. - The company is focusing on the development of advanced materials, including high-performance fibers and biodegradable materials, as part of the "14th Five-Year Plan" for industrial development[116]. Market Expansion and Strategy - The company is actively expanding its market presence in the semiconductor sector, focusing on high-performance plastic components for semiconductor manufacturing[55]. - The company has established partnerships with several medical technology firms to develop PEEK products for thoracic, orthopedic, and neurosurgical applications, enhancing its market position in the healthcare sector[56]. - The company aims to explore new application areas for PEEK materials and enhance market penetration across various industries[34]. - The company is set to launch its European overseas warehouse to enhance its brand influence and competitiveness in the global market[161]. - The company plans to enter two new international markets by Q3 2024, aiming for a 15% market share in those regions[171]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million allocated for potential deals[171]. Operational Efficiency - The company has implemented an automated control system in its main production lines, enhancing production efficiency and stability of PEEK product batches[130]. - The company has optimized its production line and capacity structure, resulting in reduced consumption of main raw materials and refined energy consumption[130]. - The company has achieved significant improvements in heat transfer efficiency and reaction completeness through optimized reactor design[60]. - The company has implemented five major management tools for product quality control, including Statistical Process Control (SPC) and Failure Mode and Effects Analysis (FMEA)[61]. Risk Management - The company faces risks related to the loss of core technical personnel, which could adversely affect production and business development due to increased competition for talent[84]. - The company is exposed to risks from fluctuations in gross margin, which could decline if it fails to innovate or if market competition intensifies[86]. - The company relies heavily on a limited number of suppliers for key raw materials, specifically fluoroketone, which constitutes approximately 54% of the production cost for PEEK powder[89]. - The company has implemented internal control systems to manage the risks associated with its expanding business scale and operational complexity[85]. Corporate Governance - The company has maintained a stable management structure with no significant changes in senior management roles during the reporting period[178]. - The company held a total of 6 board meetings during the year, with no in-person meetings[183]. - The audit committee convened 8 times during the reporting period, approving all proposed resolutions[186]. - The company has established a remuneration and assessment committee to determine the compensation plans for directors and senior management[177]. - The company’s independent directors have consistently attended board meetings and shareholder meetings, ensuring governance compliance[181].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥64,564,876.11, representing a 64.81% increase compared to ¥39,175,794.17 in the same period last year[3] - Net profit attributable to shareholders was ¥5,660,174.75, a significant increase of 6,430.46% from ¥86,673.42 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥3,690,524.76, up 1,786.46% from ¥195,632.31 in the previous year[3] - Basic and diluted earnings per share were both ¥0.05, a substantial increase from ¥0.0007 in the previous year, reflecting a growth of 7,042.86%[3] - Operating profit for Q1 2025 was ¥6,094,467.19, recovering from a loss of ¥42,448.81 in Q1 2024[18] - Net profit for Q1 2025 was ¥5,660,174.75, compared to a net profit of ¥86,673.42 in Q1 2024, indicating a substantial improvement[18] Research and Development - The company's R&D investment totaled ¥8,683,182.91, which is a 40.52% increase from ¥6,179,394.71 in the same period last year[3] - Research and development expenses increased to ¥8,311,779.66 in Q1 2025, up from ¥6,797,409.08 in Q1 2024, reflecting a focus on innovation[17] - The proportion of R&D investment to operating revenue decreased by 3.85 percentage points to 13.45% from 15.77% year-on-year[3] - The company has a significant focus on PEEK (polyether ether ketone) as a high-performance engineering plastic for various applications[11] Cash Flow and Assets - The cash flow from operating activities showed a net outflow of ¥15,053,275.83, worsening by 51.68% compared to a net outflow of ¥9,924,108.80 last year[3] - Cash and cash equivalents at the end of Q1 2025 were ¥475,977,928.33, down from ¥633,767,421.06 at the end of Q1 2024[21] - The company reported a cash balance of RMB 475,977,928.33 as of March 31, 2025, down from RMB 552,095,478.74 at the end of 2024[13] - Total assets at the end of the reporting period were ¥1,321,502,454.99, a decrease of 2.44% from ¥1,354,484,847.76 at the end of the previous year[4] - The company's current assets totaled RMB 930,751,606.54, down from RMB 988,891,466.09 at the end of 2024[14] - Total operating costs of ¥61,038,626.38 in Q1 2025, up from ¥39,590,455.27 in Q1 2024, reflecting increased operational expenses[17] Liabilities and Equity - The total liabilities decreased to RMB 143,688,303.38 from RMB 182,330,870.90 at the end of 2024[15] - The company's long-term borrowings remained stable at RMB 37,000,000.00 as of March 31, 2025[15] - Total assets and equity amounted to ¥1,321,502,454.99 and ¥1,177,814,151.61 respectively, indicating a stable financial position[16] Government Subsidies and Shareholding - The company reported a government subsidy of ¥273,971.01, which is expected to have a continuous impact on its profits[6] - The company plans to reduce shareholding by 1,216,800 shares, not exceeding 1% of the total share capital[12] Sales Performance - The company reported a significant increase in sales revenue, with cash received from sales reaching ¥32,860,007.33 in Q1 2025, compared to ¥25,135,654.35 in Q1 2024[20] - The company's revenue increased by 64.81% year-on-year, primarily due to an increase in product sales[12]

吉林省中研高分子材料股份有限公司 2024 年度财务决算报告 吉林省中研高分子材料股份有限公司（以下简称"公司"）2024 年 12 月 31 日财务报表已经北京德皓国际会计师事务所（特殊普通合伙）审计，并出具德皓 审字[2025]00000633 号标准无保留意见的《审计报告》。现将财务决算情况汇报 如下： 一、主要会计数据和财务指标 （一）主要会计数据 单位：人民币元 | 主要会计数据 | 2024 年 | 2023 年 | 本期比上年同 | | --- | --- | --- | --- | | | | | 期增减(%) | | 营业收入 | 277,091,212.17 | 291,837,050.28 | -5.05 | | 归属于上市公司股东 | 39,283,401.38 | 54,553,799.46 | -27.99 | | 的净利润 | | | | | 归属于上市公司股东 的扣除非经常性损益 | 24,531,062.63 | 40,965,439.45 | -40.12 | | 的净利润 | | | | | 经营活动产生的现金 | 51,476,358.25 | -61,681,653. ...

吉林省中研高分子材料股份有限公司 董事会关于独立董事独立性情况的评估报告 吉林省中研高分子材料股份有限公司董事会 2025 年 4 月 25 日 根据证监会《上市公司独立董事管理办法》、《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等要求，吉林省中研高分子材料股份有限公司（以下简称"公司"）董事会据此 对在任独立董事安亚人、苏志勇和周佰成的独立性情况进行评估并出具如下专项 意见： 经核查公司独立董事的任职经历以及签署的相关自查文件，董事会认为公司 独立董事符合《上市公司独立董事管理办法》《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等规定对独立董事独立性的相关要求。 ...

吉林省中研高分子材料股份有限公司 2024 年度董事会工作报告 各位股东： 2024 年度，吉林省中研高分子材料股份有限公司（以下简称"公司"）董事 会严格按照《中华人民共和国公司法》《中华人民共和国证券法》《吉林省中研高 分子材料股份有限公司章程》（以下简称"公司章程"）及《吉林省中研高分子材 料股份有限公司董事会议事规则》等规定，勤勉尽责地开展董事会各项工作，不 断规范公司法人治理结构，确保董事会科学决策和规范运作，切实维护公司和全 体股东的合法权益，保障了公司的良好运作和可持续发展。现将公司董事会 2024 年度的主要工作情况报告如下： 一、报告期内经营情况 报告期内，公司实现营业收入 27,709.12 万元，同比下降 5.05%；2024 年归 属于上市公司股东的净利润 3,928.34 万元，同比下降 27.99%；2024 年扣除非经 常性损益后的归属于上市公司股东的净利润 2,453.11 万元，同比下降 40.12%； 2024 年末公司总资产 135,448.48 万元，同比增长 8.80%；2024 年末归属于上市 公司股东的净资产 117,215.40 万元，同比增长 1.29%；20 ...

吉林省中研高分子材料股份有限公司 关于会计师事务所的履职情况评估报告 吉林省中研高分子材料股份有限公司（以下简称"公司"）聘请北京德皓国 际会计师事务所（特殊普通合伙）（以下简称"北京德皓"）作为公司 2024 年度 审计机构。根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证 券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》《国有企业、上市公司选聘会计师事务所管理办法》等法 律、法规、规定，公司对北京德皓 2024 年度审计工作的履职情况进行了评估。 具体情况如下： 一、会计师事务所基本情况 （一）会计师事务所基本信息 机构名称：北京德皓国际会计师事务所（特殊普通合伙） 成立日期：2008 年 12 月 8 日 组织形式：特殊普通合伙 注册地址：北京市西城区阜成门外大街 31 号 5 层 519A 二、2024 年会计师事务所履职情况 经评估，近一年北京德皓资质合规有效，履职能够保持独立性，勤勉尽责， 公允表达意见。具体情况如下： 首席合伙人：杨雄 （二）聘任会计师事务所履行的程序 2024 年 11 月 20 日，公司召开第四届董事会审计委员会 ...

吉林省中研高分子材料股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制评价结果推测未来内部控 ...

本次会计政策变更无需提交股东大会审议。 一、本次会计政策变更概述 （一）会计政策变更原因 财政部于 2024 年 12 月发布了《企业会计准则解释第 18 号》(财会 [2024]24 号)，规定对不属于单项履约义务的保证类质量保证产生的预计负债， 应当按确定的金额计入"主营业务成本"和"其他业务成本"，不再计入"销 售费用"。 公司自 2024 年 1 月 1 日起执行上述会计政策，将保证类质保费用计入营业 成本。 （二）变更前采用的会计政策 证券代码：688716 证券简称：中研股份 公告编号：2025-011 吉林省中研高分子材料股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会计政策变更是吉林省中研高分子材料股份有限公司(以下简称 "公司")根据中华人民共和国财政部(以下简称"财政部")发布的《企业会计 准则解释第 18 号》的相关规定进行的相应变更，不会对公司财务状况、经营成 果和现金流量产生重大影响，亦不存在损害公司及股东利益的情况。 （三）变更后采用的 ...

吉林省中研高分子材料股份有限公司 董事会审计委员会对会计师事务所 2024 年度审计工作履行监督职责的情况报告 成立日期：2008 年 12 月 8 日 组织形式：特殊普通合伙 注册地址：北京市西城区阜成门外大街 31 号 5 层 519A 首席合伙人：杨雄 截止 2023 年末，北京德皓国际合伙人 37 人，注册会计师 127 人，签署过证 券服务业务审计报告的注册会计师人数 52 人。 2023 年度经审计的收入总额为 5.49 亿元（含合并数，下同），审计业务收入 为 4.22 亿元，证券业务收入 3.30 亿元。2023 年度上市公司审计客户家数 59 家， 审计收费总额 2.41 亿元，主要涉及行业：制造业，信息传输、软件和信息服务 业，水利、环境和公共设施管理业，批发和零售业，科学研究与技术服务业。本 公司同行业上市公司审计客户家数为 0 家。 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易 所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》《国有企业、上市公司选聘会计师事务所管理办法》等法律、法 规要求及《吉林省中研高分子材料股份有 ...